oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia
Roskilde Hosp, Dept Haematol, DK-4000 Roskilde, Denmark.;Copenhagen Univ Hosp, Rigshosp, Dept Haematol, Copenhagen, Denmark..
Queens Univ Belfast, Dept Haematol, Belfast, Antrim, North Ireland..
Univ Uppsala Hosp, Dept Haematol, Uppsala, Sweden..
Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands..
Show others and affiliations
2013 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 162, no 4, 498-508 p.Article in journal (Refereed) Published
Abstract [en]

Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator-initiated, non-randomized, open-label phase II multi-centre study included 63 patients (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat was followed by a decline in clonal myeloproliferation as defined by European Leukaemia Net. Thirty patients (48%) completed the intervention period (24 weeks of therapy). An intention-to-treat response rate of 35% was identified. Pruritus was resolved [19% to 0% (P=0.06)] and the prevalence of splenomegaly was lowered from 50% to 27% (P=0.03). Sixty-five per cent of the patients experienced a decrease in JAK2 V617F allele burden (P=0.006). Thirty-three patients (52% of patients) discontinued study drug before end of intervention due to adverse events (28 patients) or lack of response (5 patients). In conclusion, vorinostat showed effectiveness by normalizing elevated leucocyte and platelet counts, resolving pruritus and significantly reducing splenomegaly. However, vorinostat was associated with significant side effects resulting in a high discontinuation rate. A lower dose of vorinostat in combination with conventional and/or novel targeted therapies may be warranted in future studies.

Place, publisher, year, edition, pages
American Society of Hematology , 2013. Vol. 162, no 4, 498-508 p.
Keyword [en]
essential thrombocythaemia, polycythaemia vera, phase II study, histone deacetylase inhibition, vorinostat
National Category
Hematology
Identifiers
URN: urn:nbn:se:oru:diva-56398DOI: 10.1111/bjh.12416ISI: 000322025200011PubMedID: 23758082OAI: oai:DiVA.org:oru-56398DiVA: diva2:1082116
Available from: 2017-03-15 Created: 2017-03-15 Last updated: 2017-03-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ahlstrand, Erik
By organisation
Orebro University Hospital
In the same journal
British Journal of Haematology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 32 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf